Alicja Starosta

Alicja Starosta

Auto-generated profile, based on publicly available information

Alicja Starosta

Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznań, Poland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
ARAnna Rugowska
Anna Rugowska
ASAlicja Starosta
Alicja Starosta
PKPatryk Konieczny
Patryk Konieczny
Duchenne muscular dystrophy (DMD) is a multisystemic disorder that affects 1:5000 boys. The severity of the phenotype varies dependent on the mutation site in theDMDgene and the resultant dystrophin expression profile. In skeletal muscle, dystrophin loss is associated with the disintegration of myofibers and their ineffective regeneration due to defective expansion and differentiation of the muscle stem cell pool. Some of these phenotypic alterations stem from the dystrophin absence-mediated serine–threonine protein kinase 2 (MARK2) misplacement/downregulation in activated muscle stem (satellite) cells and neuronal nitric oxide synthase loss in cells committed to myogenesis. Here, we trace changes in DNA methylation, histone modifications, and expression of regulatory noncoding RNAs during muscle regeneration, from the stage of satellite cells to myofibers. Furthermore, we describe the abrogation of these epigenetic regulatory processes due to changes in signal transduction in DMD and point to therapeutic treatments increasing the regenerative potential of diseased muscles based on this acquired knowledge.

11 April 2026 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
SSSylwia Szwec
Sylwia Szwec
ADAlicja Durska
Alicja Durska
PKPaulina Kościelniak
Paulina Kościelniak
JCJeffrey S. Chamberlain
Jeffrey S. Chamberlain
OOOleksandr Ostrovskyy
Oleksandr Ostrovskyy
PKPatryk Konieczny
Patryk Konieczny
Duchenne muscular dystrophy (DMD) is an X-linked disease caused by mutations in the dystrophin gene. DMD manifests with progressive skeletal muscle wasting, cardiac dysfunction, and cognitive and neuropsychiatric symptoms. As the disease progresses, affected boys lose their ability to walk and die prematurely. All DMD patients lack the full-length DP427 dystrophin, whereas approximately 10% lose all dystrophins, including DP71, synthesized in various cell types, including myoblasts. There is evidence that the cognitive symptoms of DMD patients vary depending on the location of the mutation site and the number of missing dystrophins, and there is some indication that this may also be the case in skeletal muscle. We therefore investigated the roles of DP427 and DP71 during cell proliferation and fibre differentiation. We included paralogous utrophins in our analyses, particularly the UP395 isoform, owing to its presence in muscle and its partial ability to compensate for the lack of DP427. We demonstrated that DP71 and DP427 play important roles in cell viability during cell proliferation and fibre differentiation, respectively. Despite their different expression patterns, the absence of DP71 and DP427 resulted in a similar phenotype, including increased membrane permeability, mitochondrial aggregation, elevated ROS, and increased cyto- and genotoxicity, but induced substantially different transcriptome programs associated with impaired cell proliferation and structural reorganization of myotubes, respectively. The phenotype occurred independently of myofibre contraction, dysfunction of neuromuscular or myotendinous junctions, or other cell types. We further showed that the utrophin UP395 can partially compensate not only for DP427 but also for DP71. These results explain the observed differences in disease severity among DMD patients and suggest that individuals deficient in both DP71 and DP427 may require a different therapeutic approach than patients deficient in only DP427.